1. Home
  2. ACON vs PFSA Comparison

ACON vs PFSA Comparison

Compare ACON & PFSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Aclarion Inc.

ACON

Aclarion Inc.

HOLD

Current Price

$3.55

Market Cap

3.5M

Sector

Technology

ML Signal

HOLD

PFSA

Profusa Inc.

HOLD

Current Price

$0.76

Market Cap

3.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ACON
PFSA
Founded
2008
2009
Country
United States
United States
Employees
6
N/A
Industry
Retail: Computer Software & Peripheral Equipment
Medical/Dental Instruments
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.5M
3.7M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
ACON
PFSA
Price
$3.55
$0.76
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$7.00
N/A
AVG Volume (30 Days)
52.2K
207.4K
Earning Date
05-14-2026
05-20-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$87.22
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.34
$0.05
52 Week High
$12.03
$4.22

Technical Indicators

Market Signals
Indicator
ACON
PFSA
Relative Strength Index (RSI) 59.99 50.40
Support Level $3.03 $0.09
Resistance Level $8.06 $2.22
Average True Range (ATR) 0.22 0.11
MACD 0.03 0.01
Stochastic Oscillator 93.10 66.92

Price Performance

Historical Comparison
ACON
PFSA

About ACON Aclarion Inc.

Aclarion Inc is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (MRS), and a proprietary biomarker to optimize clinical treatments. Its product Nociscan is a SaaS platform that leverages MR Spectroscopy to noninvasively help physicians distinguish between painful and nonpainful discs in the spine. The company derives its revenues from one source, the delivery of Nociscan reports to medical professionals. Substantially all revenues are generated from contracts with customers in the United States.

About PFSA Profusa Inc.

Profusa Inc is a clinical-stage digital health and medical technology company focused on developing biosensing solutions to improve health outcomes for patients with a variety of different diseases and conditions. The Company's technology enables the development of bioengineered sensors that are designed to become one with the body to detect and continuously transmit actionable, clinical-grade data for personal and medical use. The Company's first offering in the European Union, the Lumee Oxygen Platform, is designed to report reliable tissue oxygen levels at various regions of interest, both acutely and long-term.

Share on Social Networks: